GLP-1 receptor agonists may enhance the effects of desmopressin in individuals with AVP deficiency: a case series and proposed mechanism.
GLP-1 受體激動劑可能增強缺乏抗利尿激素 (AVP) 個體中 desmopressin 的效果:案例系列及提出的機制。
Pituitary 2024-09-06
The role of glucagon-like peptide-1 (GLP-1) in fluid and food intakes in vasopressin-deficient Brattleboro rats.
GLP-1在缺乏加壓素的Brattleboro大鼠中對液體和食物攝入的作用。
Physiol Behav 2024-04-02
Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.
GLP-1 受體激動劑在糖尿病心腎疾病中的作用:臨床和臨床前證據的最新更新。
Curr Diabetes Rev 2024-05-13
Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes.
結合 GLP-1 受體激動劑和胰激素類似物藥物治療來處理伴隨第一型糖尿病的肥胖。
JCEM Case Rep 2023-11-02
Renal Function Improvement With Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Type 2 Diabetes.
糖尿病患者使用胰高血糖素樣肽-1受體激動劑改善腎功能。
J Med Cases 2024-04-23
Correlation Study of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Diabetic Patients with Hypertension.
GLP-1 受體激動劑 (GLP-1RAs) 與高血壓糖尿病患者之間的相關性研究。
Iran J Public Health 2024-08-01
GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.
GLP-1RA 與 DPP-4i 在 2 型糖尿病中使用及高鉀血症與 RAS 阻斷劑停用的比率。
JAMA Intern Med 2024-08-12
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors.
在使用 SGLT2 抑制劑的超重或肥胖、糖尿病及 HFpEF 患者中,GLP-1 受體激動劑的應用。
JACC Heart Fail 2024-08-29